
At BIO 2026, Thermo Fisher's Anil Kane explains how AI is reshaping CDMO workflows and what biotechs should prioritize when choosing a development partner.

At BIO 2026, Thermo Fisher's Anil Kane explains how AI is reshaping CDMO workflows and what biotechs should prioritize when choosing a development partner.

Anil Kane, executive director, Global Head of Formulation Sciences, Pharmaceutical Development Services at Patheon discusses key parameters in the development and manufacturing of oral solid-dosage forms.

Appropriate use of sound science applied at critical junctures will improve efficiency in the high-wire act of drug development.

The author discusses how a CDMO helps in gaining process understanding and in developing robust, high-quality products and processes.

August 1st 2012

January 2nd 2016